Sucampo Pharmaceuticals (SCMP) Stock Price, Quote, News and Overview
NASDAQ:SCMP - Nasdaq -
SCMP Quote, Performance and Key Statistics
18
0 (0%)
The current stock price of SCMP is 18 null. In the past month the price decreased by -0.28%. In the past year, price increased by 52.54%.
About SCMP
Company Profile
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.
Company Info
Sucampo Pharmaceuticals
805 King Farm Boulevard Suite 550
Rockville MD 20850
CEO: Peter Greenleaf
Phone: 301-961-3400
Sucampo Pharmaceuticals / SCMP FAQ
What is the stock price of Sucampo Pharmaceuticals today?
The current stock price of SCMP is 18 null.
What is the ticker symbol for Sucampo Pharmaceuticals stock?
The exchange symbol of Sucampo Pharmaceuticals is SCMP and it is listed on the Nasdaq exchange.
On which exchange is SCMP stock listed?
SCMP stock is listed on the Nasdaq exchange.
What is Sucampo Pharmaceuticals worth?
Sucampo Pharmaceuticals (SCMP) has a market capitalization of 849.06M null. This makes SCMP a Small Cap stock.
What are the support and resistance levels for Sucampo Pharmaceuticals (SCMP) stock?
Sucampo Pharmaceuticals (SCMP) has a support level at 17.98 and a resistance level at 18.05. Check the full technical report for a detailed analysis of SCMP support and resistance levels.
Should I buy Sucampo Pharmaceuticals (SCMP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCMP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCMP, evaluating the profitability, health, valuation and growth aspects
- Sucampo Pharmaceuticals (SCMP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Sucampo Pharmaceuticals (SCMP) Sales and EPS estimates to see what analysts future expectations are.
- Sucampo Pharmaceuticals (SCMP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Sucampo Pharmaceuticals (SCMP) Insider and Institutional Ownership to learn about the owners and their transactions.
- Sucampo Pharmaceuticals (SCMP) Stock Chart to make your own analysis
- Sucampo Pharmaceuticals (SCMP) Latest news and press-releases to stay up to date.
Does Sucampo Pharmaceuticals (SCMP) stock pay dividends?
SCMP does not pay a dividend.
What is the Price/Earnings (PE) ratio of Sucampo Pharmaceuticals (SCMP)?
Sucampo Pharmaceuticals (SCMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.34).
SCMP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SCMP. When comparing the yearly performance of all stocks, SCMP is one of the better performing stocks in the market, outperforming 95.42% of all stocks.
SCMP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SCMP. Both the profitability and the financial health of SCMP get a neutral evaluation. Nothing too spectacular is happening here.
SCMP Financial Highlights
Over the last trailing twelve months SCMP reported a non-GAAP Earnings per Share(EPS) of -3.3369. The EPS decreased by -1216.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -60.24% | ||
| ROA | -38.88% | ||
| ROE | -380.71% | ||
| Debt/Equity | 7.37 |